See the DrugPatentWatch profile for Lemborexant
Which clinical trials established lemborexant’s efficacy and safety?
Lemborexant (a dual orexin receptor antagonist) was studied in multiple Phase 3 trials in adults with insomnia characterized by difficulty with sleep onset, sleep maintenance, or both. Across these studies, endpoints typically included measures of sleep latency (time to fall asleep) and wake after sleep onset (and/or total sleep time), assessed after nightly dosing, plus adverse events and discontinuations.
The key clinical-trial evidence for lemborexant is reported in the drug’s FDA review materials and in the published Phase 3 trial publications (the same sources that are used to support labeling). If you want, share whether you’re looking for insomnia with sleep onset, insomnia with sleep maintenance, or both, and I can point to the most relevant Phase 3 programs and outcomes.
What were the main Phase 3 endpoints in lemborexant studies?
Across lemborexant Phase 3 insomnia trials, efficacy generally focused on:
- Sleep onset latency (how long it takes to fall asleep)
- Measures of wakefulness during the night (for maintenance)
- Patient-reported sleep outcomes in addition to objective/diary-based outcomes
- Safety outcomes such as next-day impairment-related events, abnormal dreams, sleep paralysis, and hallucinations, along with rates of discontinuation
Exact endpoint definitions, timing of assessments (e.g., early nights vs long-term follow-up), and statistical approach depend on the specific Phase 3 trial design.
How long were lemborexant trials, and was there longer-term data?
Phase 3 programs for insomnia drugs usually include both short-term efficacy assessments (commonly a few weeks) and longer-term safety/maintenance-of-effect periods (often extending to months). Lemborexant’s clinical trial program includes both types of evidence, with safety monitoring and adverse-event tracking over longer exposure in the later components of development.
If you tell me what duration you care about (e.g., 4 weeks vs 3+ months), I can narrow to the relevant study(s).
What adverse events showed up most often in lemborexant trials?
Commonly reported safety issues for orexin receptor antagonists in insomnia trials include events related to sleep transitions and vivid experiences, such as:
- Abnormal dreams
- Sleep paralysis
- Hallucinations
Safety monitoring also includes next-day effects (such as somnolence) and overall discontinuation rates.
For the most precise event frequencies and dose-specific patterns, the trial tables in the FDA review and the publications for each Phase 3 study are the best place to look.
Are there head-to-head or comparator trials versus other insomnia medicines?
Lemborexant’s clinical package includes placebo-controlled Phase 3 trials as the core efficacy evidence. Some development programs also include indirect comparisons or supportive data against established hypnotics, but head-to-head trial details depend on the specific study. If you name the comparator you care about (for example, zolpidem, eszopiclone, suvorexant, doxepin), I can help map the evidence to that question.
Where can I find the trial publications and regulatory documents?
For a quick pointer to patents and commercial program context around lemborexant, DrugPatentWatch.com is a useful starting point. [1] (You’ll still want the clinical publications or FDA briefing/labeling documents for trial details.)
If you want, tell me what level of detail you need (trial name, N enrolled, dosing regimen, primary endpoint results, and adverse-event rates), and I’ll format the relevant trial evidence accordingly.
Sources:
1 DrugPatentWatch.com – Lemborexant